CN104587160B - A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache - Google Patents
A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache Download PDFInfo
- Publication number
- CN104587160B CN104587160B CN201510072621.5A CN201510072621A CN104587160B CN 104587160 B CN104587160 B CN 104587160B CN 201510072621 A CN201510072621 A CN 201510072621A CN 104587160 B CN104587160 B CN 104587160B
- Authority
- CN
- China
- Prior art keywords
- radix
- headache
- chinese medicine
- medicine composition
- lumbar anesthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 206010019233 Headaches Diseases 0.000 title claims abstract description 30
- 231100000869 headache Toxicity 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 206010002091 Anaesthesia Diseases 0.000 title claims abstract description 23
- 230000037005 anaesthesia Effects 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 241001643642 Viticis Species 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 241000628997 Flos Species 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000002693 spinal anesthesia Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The invention belongs to technical field of Chinese medicines, a kind of treat lumbar anesthesia after the Chinese medicine of having a headache, be prepared from by following Chinese crude drug: Radix Ginseng, the Radix Angelicae Dahuricae, Radix Asparagi, the Radix Astragali, Radix Paeoniae Rubra, Radix Bupleuri, Semen Persicae, Radix Achyranthis Bidentatae, Fructus Viticis and Flos Osmanthi Fragrantis.The present invention has a headache Chinese medicine composition synergism by force after treating lumbar anesthesia, have YIN nourishing and increase liquid, dispelling wind and removing obstruction in the collateral, the effect such as heat-clearing and toxic substances removing, anti-inflammatory analgesic, all medicines share the effect can playing treatment headache.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache and preparation method thereof.
Background technology
Anesthesia is existing to be widely used.Subarachnoid block anesthesia is clinical conventional a kind of anesthesia, local anaesthetics is injected into subarachnoid space, act on spinal nerve root and make corresponding site produce the method for anesthetic action, be called subarachnoid block, practise and claim spinal anesthesia (spinalanesthesia), be called for short lumbar anesthesia.
After spinal anesthesia, headache is one of common complication of subarachnoid anesthesia, and the pin hole stayed on spinal dura mater due to puncture needle often constantly spills cerebrospinal fluid and caused.Have a headache after spinal anesthesia, namely generally there is symptom in postoperative 2d, most of patient through infusion and in symptomatic treatment a couple of days symptom can alleviate, but the heavy patient of small part is not good through general treatment, even recurrent exerbation.
Related documents is reported, to intractable or by the invalid headache of expectant treatment, available autoblood wears at former waist the epidural space blood completion method treatment that epidural space is injected at position by sterile working's method, and reusable to recidivist.Also has drop-method in application normal saline 500ml epidural space, headache can be made obviously to alleviate, although above 2 kinds of methods are effective, but all have traumatic, especially patient has fear to rachicentesis, great majority are reluctant to accept again, its technical requirement is higher, need strict aseptic technique, and be postoperative position, inconvenience is brought to operation.
Summary of the invention
In order to solve the above-mentioned technical problem existed in prior art, the invention provides a kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache.
In order to realize object of the present invention, the present invention adopts following technical scheme to realize:
A Chinese medicine composition of having a headache after treating lumbar anesthesia, is characterized in that, is prepared from by following Chinese crude drug:
Radix Ginseng, the Radix Angelicae Dahuricae, Radix Asparagi, the Radix Astragali, Radix Paeoniae Rubra, Radix Bupleuri, Semen Persicae, Radix Achyranthis Bidentatae, Fructus Viticis and Flos Osmanthi Fragrantis.
Preferably, the Chinese medicine composition that the present invention has a headache after treating lumbar anesthesia, is prepared from by the raw material of following weight portion:
Radix Angelicae Dahuricae 40-80, Radix Asparagi 40-80, Radix Ginseng 30-66, Radix Astragali 12-36, Radix Paeoniae Rubra 12-36, Radix Bupleuri 12-36, Semen Persicae 12-36, Radix Achyranthis Bidentatae 12-24, Fructus Viticis 12-24 and Flos Osmanthi Fragrantis 6-18.
Further preferably, the present invention has a headache after treating lumbar anesthesia Chinese medicine composition, is prepared from by the raw material of following weight portion:
The Radix Angelicae Dahuricae 68, Radix Asparagi 68, Radix Ginseng 48, the Radix Astragali 24, Radix Paeoniae Rubra 24, Radix Bupleuri 24, Semen Persicae 20, Radix Achyranthis Bidentatae 18, Fructus Viticis 18 and Flos Osmanthi Fragrantis 12.
Preferably, the present invention's Chinese medicine composition of having a headache after treating lumbar anesthesia can be prepared into tablet, dispersible tablet, granule, capsule or decoction, is preferably capsule.
Preferably, as required, Chinese medicine composition of the present invention can also add pharmaceutically acceptable carrier.
Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc.
Preferably, filler of the present invention has: starch, Icing Sugar, calcium phosphate, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.;
Described binding agent has: sodium carboxymethyl cellulose, PVP-K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, gelling starch etc.;
Described disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose etc.;
Described lubricant has: magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micropowder silica gel etc.
Present invention also offers a kind of treat lumbar anesthesia after to have a headache the preparation method of Chinese medicinal composition capsules agent, comprise following steps:
Take dried Radix Ginseng, the Radix Angelicae Dahuricae, Radix Asparagi, the Radix Astragali, Radix Paeoniae Rubra, Radix Bupleuri, Semen Persicae, Radix Achyranthis Bidentatae, Fructus Viticis and Flos Osmanthi Fragrantis by weight portion of the present invention, be ground into 80 object fine powders, mix homogeneously, sterilizing is prepared into capsule, and every containing crude drug amount 0.4g.
Capsule usage and dosage of the present invention: every day 3 times, each 4-6 grain.5 days courses for the treatment of.
Chinese medicine composition synergism of having a headache after the present invention's treatment lumbar anesthesia is strong, there is YIN nourishing and increase liquid, dispelling wind and removing obstruction in the collateral, the effect such as heat-clearing and toxic substances removing, anti-inflammatory analgesic, all medicines share and are conducive to spinal dura mater reparation and healing, prevent cerebrospinal fluid from continuing to leak outside, make cerebrospinal fluid and cerebral recover normal, thus headache is disappeared.
To have a headache Chinese medicine composition after clinical experiment proved invention treatment lumbar anesthesia, there is dosage few, effective percentage is high, short treating period, the advantage such as have no side effect, and Chinese medicinal composition preparation preparation technology of the present invention is simple, is suitable for promoting the use of clinically.
Detailed description of the invention
Below in conjunction with concrete embodiment, further restriction is done to technical scheme of the present invention, but claimed scope is not only confined to done description.
Embodiment 1
Ingredients is taken: the Radix Angelicae Dahuricae 68, Radix Asparagi 68, Radix Ginseng 48, the Radix Astragali 24, Radix Paeoniae Rubra 24, Radix Bupleuri 24, Semen Persicae 20, Radix Achyranthis Bidentatae 18, Fructus Viticis 18 and Flos Osmanthi Fragrantis 12 by following weight portion, be ground into 80 object fine powders, mix homogeneously, sterilizing is prepared into capsule, and every containing crude drug amount 0.4g.
Embodiment 2
Ingredients is taken: the Radix Angelicae Dahuricae 80, Radix Asparagi 68, Radix Ginseng 60, the Radix Astragali 30, Radix Paeoniae Rubra 18, Radix Bupleuri 30, Semen Persicae 24, Radix Achyranthis Bidentatae 24, Fructus Viticis 24 and Flos Osmanthi Fragrantis 18 by following weight portion, be ground into 80 object fine powders, mix homogeneously, sterilizing is prepared into capsule, and every containing crude drug amount 0.4g.
Embodiment 3
Ingredients is taken: the Radix Angelicae Dahuricae 48, Radix Asparagi 80, Radix Ginseng 66, the Radix Astragali 36, Radix Paeoniae Rubra 24, Radix Bupleuri 12, Semen Persicae 12, Radix Achyranthis Bidentatae 12, Fructus Viticis 12 and Flos Osmanthi Fragrantis 6 by following weight portion, be ground into 80 object fine powders, mix homogeneously, sterilizing is prepared into capsule, and every containing crude drug amount 0.4g.
Comparative example 1
Ingredients is taken: the Radix Angelicae Dahuricae 68, Radix Asparagi 68, Radix Ginseng 48, the Radix Astragali 24, Radix Paeoniae Rubra 24, Radix Bupleuri 24, Semen Persicae 20, Radix Achyranthis Bidentatae 18 and Fructus Viticis 18 by following weight portion, be ground into 80 object fine powders, mix homogeneously, sterilizing is prepared into capsule, and every containing crude drug amount 0.4g.
Clinical observation material
1. data and method
1.1 physical data
Postoperatively there is spinal anesthesia (lumbar anesthesia) headache person 121 example afterwards in that selects here in December ,-2014 is accepted for medical treatment in January, 2013.Wherein male 50 example, women 71 example.Patient age 23 ~ 69 years old, the median age 40 years old.All patients all without serious hepatic and kidney function obstacle, without coagulation disorders, free-event survival medical history, previously without medical history of having a headache for a long time.
1.2 clinical manifestation
All patient's headaches all come across in postoperative 2d, are light moderate pain.Painful area is mainly top occipitalia, and indivedual accumulative bilateral temples and bilateral forehead, pain and position are obviously relevant, alleviate when putting down sleeping.A small amount of patient with mild nausea, but without symptoms of emesis.
1.3 grouping
According to randomly assigne patient is divided into and all patients are divided into 3 groups at random: contrast 1 group of 50 example, treatment group 50 example, contrast 2 group of 21 example.Each group of patient no difference of science of statistics in age distribution, sex ratio, weight, lab testing, has comparability.
1.4 Therapeutic Method
Contrasting 1 group only adopts conventional western medicine to treat, and goes pillow flat sleeping, and every day, amount of infusion 2500ml vitimin supplement C and vitamin B6, and drank more water after enterokinesia recovers, and to the obvious person of gastrointestinal symptom, gave the medicines such as metoclopramide in right amount.
Treatment group is treated on basis at employing conventional western medicine, capsule prepared by the oral embodiment of the present invention 1, every day 3 times, each 6.
Contrast 2 groups on employing conventional western medicine treatment basis, capsule prepared by oral comparative example 1 of the present invention, every day 3 times, each 6.
Three groups of patients treat 5 days all continuously.The all patients of treatments period should ensure sufficient sleep, suitably carry out restorative motion.
1.5 statistical method
Data acquisition SPSS17.0 software carries out statistical analysis, measurement data with
represent, compare between group and adopt t inspection; Enumeration data adopts X
2inspection.P < 0.05 represents that difference has statistical significance.
1.6 criterion of therapeutical effect
Cure: the symptoms such as headache, dizziness, nausea and vomiting disappear completely, do not recur, and laboratory inspection are normal after drug withdrawal.
Effective: the transference cures such as headache, dizziness, nausea and vomiting but after drug withdrawal repeatedly or the symptom such as headache, dizziness, nausea and vomiting alleviate, lab testing makes moderate progress;
Invalid: symptom and lab testing are all without improvement.
2. result, see table 1
Table 1, Clinical efficacy comparison
| Group | Case load | Cure (cure rate) | Effectively (effective percentage) | Invalid (inefficiency) | Total effective rate |
| Contrast 1 group | 50 | 17(34.0％) | 17(34.0％) | 16(32.0％) | 68.0％ |
| Treatment group | 50 | 38(76.0％) | 9(18.0％) | 3(6.0％) | 94.0％ |
| Contrast 2 groups | 21 | 8 | 7 | 6 | 71.4％ |
Visible treatment group cure rate or total effective rate all have significant difference compared with contrast 1 group, have statistical significance (P < 0.05).Though contrast 1 group have certain difference with contrast 2 groups of total effective rates, difference is not obvious, does not have statistical significance.In experimentation, all patients are and occur obvious adverse reaction.
Above-mentioned clinical trial results proved invention cured substance rate is high, and the headache reaction occurred after can effectively treating spinal anesthesia in patients, patient compliance is high.Simultaneously also proved invention Chinese medicine composition synergism is extremely strong, can gain potentiation mutually, indispensable in use.
The technology contents of the not detailed description of the invention described above is known technology.
Claims (4)
1. a Chinese medicine composition of having a headache after treating lumbar anesthesia, is characterized in that, is prepared from by the crude drug of following weight portion:
Radix Angelicae Dahuricae 40-80, Radix Asparagi 40-80, Radix Ginseng 30-66, Radix Astragali 12-36, Radix Paeoniae Rubra 12-36, Radix Bupleuri 12-36, Semen Persicae 12-36, Radix Achyranthis Bidentatae 12-24, Fructus Viticis 12-24 and Flos Osmanthi Fragrantis 6-18.
2. the Chinese medicine composition of having a headache after treatment lumbar anesthesia as claimed in claim 1, is characterized in that, be prepared from by the crude drug of following weight portion:
The Radix Angelicae Dahuricae 68, Radix Asparagi 68, Radix Ginseng 48, the Radix Astragali 24, Radix Paeoniae Rubra 24, Radix Bupleuri 24, Semen Persicae 20, Radix Achyranthis Bidentatae 18, Fructus Viticis 18 and Flos Osmanthi Fragrantis 12.
3. the Chinese medicine composition of having a headache after treatment lumbar anesthesia as claimed in claim 1, it is characterized in that, it is tablet, granule, capsule or decoction.
4. the Chinese medicine composition of having a headache after treatment lumbar anesthesia as claimed in claim 3, it is characterized in that, it is capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510072621.5A CN104587160B (en) | 2015-02-11 | 2015-02-11 | A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510072621.5A CN104587160B (en) | 2015-02-11 | 2015-02-11 | A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104587160A CN104587160A (en) | 2015-05-06 |
| CN104587160B true CN104587160B (en) | 2016-03-16 |
Family
ID=53113431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510072621.5A Expired - Fee Related CN104587160B (en) | 2015-02-11 | 2015-02-11 | A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104587160B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535751A (en) * | 2016-01-15 | 2016-05-04 | 夏承生 | Traditional Chinese medicine for treating postdural puncture headache and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961512A (en) * | 2012-12-05 | 2013-03-13 | 江苏老蚕坊蚕桑生物科技开发有限公司 | Traditional Chinese medicine for treating vascular headache |
-
2015
- 2015-02-11 CN CN201510072621.5A patent/CN104587160B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961512A (en) * | 2012-12-05 | 2013-03-13 | 江苏老蚕坊蚕桑生物科技开发有限公司 | Traditional Chinese medicine for treating vascular headache |
Non-Patent Citations (2)
| Title |
|---|
| 腰麻后顽固性头痛治疗1例;卢启胜等;《医药产业资讯》;20051031;第2卷(第18期);113 * |
| 补中益气汤加减治疗腰麻后低颅压综合征40例;李淑萍等;《新疆中医药》;20121231;第30卷(第4期);146-147 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104587160A (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657821B (en) | Drug for treating ovarian cyst | |
| CN104587160B (en) | A kind of treat lumbar anesthesia after the Chinese medicine composition of having a headache | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN103301215B (en) | Pharmaceutical composition for treating bone disease as well as preparation method and use thereof | |
| CN103285205B (en) | Ruyi bone connection paste | |
| CN102406792B (en) | Pharmaceutical composition for rapidly promoting healing of bone fracture | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN105194572A (en) | Traditional Chinese medicine composition for treating gliomas | |
| CN104984020A (en) | Traditional Chinese medicinal preparation for treating hysteromyoma, and preparation method thereof | |
| CN1799599A (en) | Medicine for treating joint disease | |
| CN104707035B (en) | A kind of Chinese medicine composition for the treatment of combined spinal-epidural anesthesia Headache | |
| CN104258113B (en) | A kind of Chinese medicine composition for the treatment of cerebral hemorrhage | |
| CN100353995C (en) | Pharmaceutical composition with functions of dispersing pathogenic wind, activating collaterals ,and clearing away toxin | |
| CN105497267A (en) | Traditional Chinese medicine composition for treating extreme noxious heat type infantile jaundice | |
| CN101954043A (en) | Medicament for treating hyperosteogeny and preparation method thereof | |
| CN100434103C (en) | Chinese medicine composition for treating anemogenous-ache disease | |
| CN1935211A (en) | Medicinal composition for treating cerebral ischemia | |
| CN104623415A (en) | Pharmaceutical composition for treating nephropathy and application thereof | |
| CN105535817A (en) | A traditional Chinese medicine composition containing argy wormwood leaves and used for treating cervical spondylosis and a preparing method thereof | |
| CN105213815A (en) | Chinese medicine composition being used for the treatment of cervical spondylosis and preparation method thereof | |
| CN105343741A (en) | Traditional Chinese medicine for treating thyroid tumor and preparation method of traditional Chinese medicine | |
| CN104689217B (en) | A kind of Chinese medicine composition for the treatment of gastric cancer | |
| CN104324162A (en) | Traditional Chinese medicine composition for treating kidney deficiency type lumbar disc herniation and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Peng Juan Inventor after: Yu Wengang Inventor after: Xue Feng Inventor after: Wang Li Inventor after: Gao Ronglei Inventor before: Ren Xiaoju |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160223 Address after: 266005 Shandong city of Qingdao province Jiangsu City Road No. 16 Applicant after: Peng Juan Address before: 276401 Yishui City, Linyi province Yishui County town of new lane, No. 18 Applicant before: Wang Guixia |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 |